PESG Research releases a new market update on Silexion Therapeutics (NASDAQ: SLXN). Silexion recently announced the completion of its initial study evaluating SIL-204 in orthotopic pancreatic cancer ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback